CORONA Remedies Limited (NSE:CORONA)

CORONA Remedies Statistics

Total Valuation

CORONA Remedies has a market cap or net worth of INR 85.05 billion. The enterprise value is 85.14 billion.

Market Cap	85.05B
Enterprise Value	85.14B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

CORONA Remedies has 61.16 million shares outstanding. The number of shares has decreased by -0.04% in one year.

Current Share Class	61.16M
Shares Outstanding	61.16M
Shares Change (YoY)	-0.04%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	69.00%
Owned by Institutions (%)	0.74%
Float	6.17M

Valuation Ratios

The trailing PE ratio is 48.59.

PE Ratio	48.59
Forward PE	n/a
PS Ratio	6.55
PB Ratio	12.89
P/TBV Ratio	17.30
P/FCF Ratio	73.44
P/OCF Ratio	42.70
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 31.22, with an EV/FCF ratio of 73.52.

EV / Earnings	48.64
EV / Sales	6.55
EV / EBITDA	31.22
EV / EBIT	36.21
EV / FCF	73.52

Financial Position

The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.10.

Current Ratio	1.43
Quick Ratio	0.88
Debt / Equity	0.10
Debt / EBITDA	0.23
Debt / FCF	0.54
Interest Coverage	28.42

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	26.06%
Return on Capital Employed (ROCE)	31.97%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	2.89M
Profits Per Employee	388,964
Employee Count	4,508
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, CORONA Remedies has paid 573.39 million in taxes.

Income Tax	573.39M
Effective Tax Rate	24.68%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	45.85
Average Volume (20 Days)	132,961

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CORONA Remedies had revenue of INR 12.99 billion and earned 1.75 billion in profits. Earnings per share was 28.62.

Revenue	12.99B
Gross Profit	10.46B
Operating Income	2.35B
Pretax Income	2.32B
Net Income	1.75B
EBITDA	2.69B
EBIT	2.35B
Earnings Per Share (EPS)	28.62

Balance Sheet

The company has 539.60 million in cash and 627.10 million in debt, with a net cash position of -87.50 million or -1.43 per share.

Cash & Cash Equivalents	539.60M
Total Debt	627.10M
Net Cash	-87.50M
Net Cash Per Share	-1.43
Equity (Book Value)	6.60B
Book Value Per Share	107.80
Working Capital	1.03B

Cash Flow

In the last 12 months, operating cash flow was 1.99 billion and capital expenditures -833.58 million, giving a free cash flow of 1.16 billion.

Operating Cash Flow	1.99B
Capital Expenditures	-833.58M
Free Cash Flow	1.16B
FCF Per Share	18.94

Margins

Gross margin is 80.52%, with operating and profit margins of 18.07% and 13.47%.

Gross Margin	80.52%
Operating Margin	18.07%
Pretax Margin	17.89%
Profit Margin	13.47%
EBITDA Margin	20.70%
EBIT Margin	18.07%
FCF Margin	8.91%

Dividends & Yields

CORONA Remedies does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	25.54%
Buyback Yield	0.04%
Shareholder Yield	0.04%
Earnings Yield	2.06%
FCF Yield	1.36%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3